New Drugs 2024: State Pharmaceuticals Expansion

Sri Lanka’s SPMC to Expand Pharmaceutical production with New Facilities and Medicines

The State Pharmaceuticals Manufacturing Corporation (SPMC) is poised for significant expansion, announcing plans to introduce 10 new medicines to the market this year and increase production to 4,000 million tablets and capsules. These developments signal a strengthening of Sri Lanka’s domestic pharmaceutical capabilities and a commitment to bolstering public health infrastructure.

Did you know? – The SPMC plays a vital role in ensuring sri Lanka has access to affordable medicines, reducing dependence on frequently enough more expensive imports and bolstering national health security.

Record Production in 2025 Fuels Expansion

The SPMC achieved a landmark year in 2025, reaching its highest-ever production volume with 3,625 million tablets and capsules manufactured. This success, coupled with the accomplished introduction of five new drug types during the same period, has paved the way for ambitious growth targets. “This demonstrates the SPMC’s increasing capacity and commitment to providing essential medicines,” a senior official stated.

Pro tip – Increased domestic pharmaceutical production can shield a country from global supply chain disruptions,as seen during recent health crises,ensuring consistent access to vital medications.

New infrastructure to Support Growing Demand

To accommodate increased production and ensure efficient distribution, the SPMC is investing heavily in new infrastructure.A two-story pharmaceutical warehouse complex near the SPMC premises in Ratmalana is scheduled to open in march. This facility will significantly enhance storage capacity and streamline logistics.

Furthermore, plans are underway to construct a thorough pharmaceutical storage complex alongside a modern manufacturing and packaging facility in Millewa, Horana. This expansion represents a long-term investment in the country’s pharmaceutical independence.

Current Manufacturing Capabilities

Currently,the SPMC manufactures 70 types of medicines,serving a critical role in providing affordable and accessible healthcare solutions to the Sri Lankan population. The planned introduction of 10 additional medicines will broaden the range of treatments available domestically, reducing reliance on imports.

The SPMC’s strategic investments in both production capacity and infrastructure underscore its commitment to strengthening Sri Lanka’s pharmaceutical sector and ensuring a reliable supply of essential medicines for years to come.

Reader question – How might increased local pharmaceutical production impact the cost of healthcare for Sri Lankan citizens? Share your thoughts!